SOURCE: CLX Investment Company, Inc.

September 19, 2006 09:21 ET

CLX Investment Company Announces Zonda Distribution Agreement for HandiLab Test in Turkey

TEMECULA, CA -- (MARKET WIRE) -- September 19, 2006 -- CLX Investment Company, Inc. (OTCBB: CLXN), a diversified investment fund with holdings in e-learning, global advertising and diagnostic testing markets, today announced that portfolio investment Zonda Incorporated has entered into a distribution agreement to introduce its HandiLab-C test for chlamydia in Turkey.

The HandiLab-C test is the only over-the-counter test (self testing) for chlamydia that carries the CE mark, which signifies that the product complies with the relevant European Union health, safety, and environmental protection requirements. The HandiLab-C and other medical diagnostic tests in the HandiLab line also carry CE approval for professional use in European countries.

"We continue to find highly receptive markets for the HandiLab-C test in Europe, and there is considerable interest among distributors who would like to represent Zonda products," said Laurie J. Oleksiewicz, president of Zonda, Incorporated.

Zonda Incorporated, in which CLX holds a 31% equity interest, specializes in diagnostic tests that serve the medical, food safety, cosmetic, beverage, pharmaceutical, veterinary, and environmental sanitation testing markets.

Robert McCoy, chairman and chief executive officer of CLX Investment Company, commented, "In fairly short order, we expect that the HandiLab-C will be found on pharmacy shelves in virtually every country in Europe. Since it is also approved for professional use in doctors' offices, hospitals and clinics, we expect to see growth into these locations as well. Zonda is successfully executing its expansion strategy, and we look forward to increased value for this portfolio investment."

To sign up to receive information by email directly from CLX Investment Company when new press releases, investor newsletters, SEC filings, or other information is disclosed, please visit

About Zonda, Incorporated

Zonda, Inc. (, in which CLX holds a 31% equity interest, specializes in diagnostic tests that serve the medical, food safety, cosmetic, beverage, pharmaceutical, veterinary, and environmental sanitation testing markets. Zonda's product line includes innovative, rapid, self-contained diagnostic devices for the detection of chlamydia, gonorrhea, yeast (Candida albicans) and Group A Strep, tests that detect bacterial and other potential harmful micro-organisms on surfaces, and confirmation tests for a wide variety of bacteria. The HandiLab-C test for chlamydia carries a CE mark for both professional point-of-care and over-the-counter use. The gonorrhea, yeast and Group A Strep tests carry CE marks for professional point-of-care use, and Zonda is seeking similar approvals for over-the-counter sales of these products. Each of the Zonda infectious disease tests are marketed as superior to their competition due to their comparable accuracy (compared directly to PCR or DNA testing), ease of use, compact design, long shelf life, rapid results, and cost effectiveness.

About CLX Investment Company

CLX Investment Company ( holds a 31% equity interest in Zonda, Inc. ( Also in the CLX investment portfolio is a 49% interest in eStrategy Solutions, Inc. (, a Texas-based e-learning provider that has developed online training solutions for government entities and other professional organizations. CLX has invested, and holds a common stock position, in ActionView International, Inc. (, a publicly traded global manufacturer and marketer of "smart" scrolling advertising billboards.

CLX has elected to be regulated as a Business Development Company pursuant to Section 54 of the Investment Company Act of 1940, and is pursuing a business plan wherein the Company seeks to make investment in developing companies with the goal of providing return for its shareholders.

All statements included in this release, including statements regarding potential future plans and objectives of CLX Investments are forward-looking statements. Such statements are necessarily subject to risks and uncertainties, some of which are significant in scope and nature beyond CLX Investments' control. There can be no assurance that such statements will prove accurate. Actual results and future events could differ materially from those anticipated in such statements depending on many factors. Historical results are not necessarily indicative of future performance.

Contact Information

  • Contact:
    Gemini Financial Communications
    A. Beyer
    Email Contact